Neurophet said on the 21st that it has appointed Lawrence N. Tanenbaum, a world-renowned neuroimaging expert, as a scientific advisory board member. The strategy is to accelerate the expansion of its medical imaging artificial intelligence (AI) business based on a North American clinical network.
Tanenbaum is a global scholar who has spent more than 30 years across clinical, research, and industry settings in neuroimaging. He has contributed to advances in cutting-edge technologies based on medical imaging AI, magnetic resonance imaging (MRI), and computed tomography (CT).
Tanenbaum served as vice president and chief technology officer (CTO) at RadNet, the largest U.S. outpatient imaging diagnostics company, leading the clinical adoption and industrialization of medical imaging technologies. He also held a professorship in radiology at the Icahn School of Medicine at Mount Sinai in the United States, pursuing academic research in parallel.
Tanenbaum is recognized for his influence in the global medical imaging field, serving as a fellow of the American College of Radiology (ACR) and as a distinguished scientific advisor for the Radiological Society of North America (RSNA).
Neurophet plans to use this appointment to strengthen the clinical applicability of its brain image–based medical AI technologies and to expand collaboration with major medical institutions and corporations by leveraging its North America–centered global clinical network.
Tanenbaum said, "I strongly resonated with Neurophet's technological capabilities and vision," adding, "I will actively contribute so that AI-based medical imaging technologies can create greater value in real clinical settings."
Bin Jun-gil, co-CEO of Neurophet, said, "Tanenbaum is one of the world's leading experts in the convergence of medical imaging and AI," adding, "With this appointment, we will raise our clinical credibility to a global level and accelerate efforts to strengthen our overseas business competitiveness centered on the U.S. market."